Rusfertide, a peptide mimetic of natural hepcidin, targets and degrades ferroportin, thereby reducing serum iron and transferrin saturation, which helps regulate red blood cell production. It ameliorates conditions such as polycythemia vera, β-thalassemia, and hereditary hemochromatosis [1] [2].

Rusfertide 限制红细胞（RBCs）中的铁毒性（1 mg/kg，皮下注射，每两天一次，共49天）和转铁蛋白饱和度（2.5 mg/kg，皮下注射，每两天一次，共2周），提高红细胞的携氧能力，改善β-地中海贫血和遗传性血色素沉着症小鼠模型中的贫血和铁沉积，提高RBCs的生存率，减少转铁蛋白饱和度和铁沉积 [1]。 Animal Model: Hbb th3/+ mice model for β-thalassemia and hereditary hemochromatosis [1] Dosage: 1 and 2.5 mg/kg Administration: s.c., once every two days, for 49 days (1 mg/kg); or for 2 weeks (2.5 mg/kg) Result: Improved the survival rate of RBCs in β-thalassemia model. Reduced transferrin-saturation and iron deposition.